基于生物信息库病例分析ECT2在子宫内膜癌中的表达及临床意义

doi:10.6040/j.issn.1671-7554.0.2022.1479

摘要/Abstract

摘要： 目的通过多种数据库分析ECT2在子宫内膜癌(UCEC)的表达水平、预后情况及潜在功能。方法利用GEO、STRING、Cytoscape筛选UCEC关键基因。联合TIMER2.0、UALCAN、肿瘤基因组图谱(TCGA)进行预后分析,运用LinkedOmics及Metascape在线分析工具行共表达基因筛选和功能富集分析。TIMER2.0分析关键基因与多肿瘤免疫浸润细胞关联性。结果共筛选出245个DEGs,ECT2为关键基因,其表达水平与UCEC肿瘤分级、分期及预后生存期有关联,另外发现ECT2与肿瘤增殖和免疫浸润细胞有关联。结论 ECT2在UCEC中高表达,且与UCEC的不良预后有一定的关联性,这可能为UCEC治疗提供新靶点。

关键词: 子宫内膜癌, GEO数据库, 生物信息学分析, 免疫细胞, 细胞周期

Abstract: Objective To analyze the expression and potential function of ECT2 in uterine corpus endometrial carcinoma(UCEC)through multiple databases and to explore the prognosis. Methods The hub genes of UCEC were screened with GEO, STRING and Cytoscape. Kaplan-Meier analysis was performed in combination with TIMER2.0, UALCAN and Tumor Genome Atlas(TCGA). The differentially expressed genes(DEGs)were screened and functional enrichment analysis was performed using online analysis tools of Linked Omics and Metascape. The correlation between hub genes and pan-cancer immune infiltrating cells was analyzed with TIMER2.0. Results A total of 245 DEGs were screened out. ECT2 was the key gene, and its expression was correlated with the grade, stage, prognosis and survival of UCEC patients. ECT2 was also correlated with tumor proliferation and immune infiltration. Conclusion ECT2 is highly expressed in UCEC and closely related to the dismal prognosis, which may provide a new target for the treatment of this disease.

Key words: Uterine corpus endometrial carcinoma, GEO datebase, Bioinformatics analysis, Immune cells, Cell cycle

中图分类号:

R737.33

刘腾,马迎春. 基于生物信息库病例分析ECT2在子宫内膜癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(8): 63-71.

LIU Teng, MA Yingchun. Expression of ECT2 in uterine corpus endometrial carcinoma and its clinical significance based on bioinformatics database[J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 63-71.

参考文献

[1] Matteson KA, Robison K, Jacoby VL. Opportunities for early detection of endometrial cancer in women with postmenopausal bleeding[J]. JAMA Intern Med, 2018, 178(9): 1222-1223.
[2] Ledford LRC, Lockwood S. Scope and epidemiology of gynecologic cancers: an overview[J]. Semin Oncol Nurs, 2019, 35(2): 147-150.
[3] Chen S, Wang LL, Sun KX, et al. LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(9 Pt B): 3013-3021.
[4] 王铭洋, 范文生, 叶明侠, 等. 子宫内膜癌分子分型及临床应用研究进展[J]. 现代妇产科进展, 2021, 30(4): 307-310, 313.
[5] Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma[J]. Annu Rev Pathol, 2019, 14: 339-367. doi: 10.1146/annurev-pathol-020117-043609.
[6] Pedersen CB, Nielsen FC, Rossing M, et al. Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing[J]. Mol Oncol, 2018, 12(12): 2136-2146.
[7] Vasaikar S, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46: D956-D963.
[8] Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J]. Nat Commun, 2019, 10(1): 1523.
[9] Irvin WP, Rice LW, Berkowitz RS. Advances in the management of endometrial adenocarcinoma. A review[J]. J Reprod Med, 2002, 47(3): 173-190.
[10] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
[11] Arend RL, Jones BA, Martinez A, et al. Endometrial cancer: molecular markers and management of advanced stage disease[J]. Gynecol Oncol, 2018, 150(3): 569-580.
[12] Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma[J]. Gynecol Oncol, 2017, 145(1): 200-207.
[13] Nuñez-Olvera SI, Gallardo-Rincón D, Puente-Rivera J, et al. Autophagy machinery as a promising therapeutic target in endometrial cancer[J]. Front Oncol, 2019, 9: 1326. doi: 10.3389/fonc.2019.01326.
[14] Raffone A, Travaglino A, Mascolo M, et al. Histopathological characterization of ProMisE molecular groups of endometrial cancer[J]. Gynecol Oncol, 2020, 157(1): 252-259.
[15] Xu D, Wang Y, Wu J, et al. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway[J]. Cell Death Dis, 2021, 12(2): 162.
[16] Zhang H, Geng Y, Sun C, et al. Upregulation of ECT2 predicts adverse clinical outcomes and increases 5-fluorouracil resistance in gastric cancer patients[J]. J Oncol, 2021, 2021: 2102890. doi: 10.1155/2021/2102890.
[17] Wang H, Liu H, Li J, et al. Effect of ECT2 expression on the growth of triple-negative breast cancer cells with paclitaxel intervention[J]. Onco Targets Ther, 2020, 13: 12905-12918. doi: 10.2147/OTT.S275725.
[18] Yang Q, Yu B, Sun J. TTK, CDC25A, and ESPL1 as prognostic biomarkers for endometrial cancer[J]. Biomed Res Int, 2020, 2020: 4625123. doi: 10.1155/2020/4625123.
[19] Liu J, Wu Z, Sun R, et al. Using mRNAsi to identify prognostic-related genes in endometrial carcinoma based on WGCNA[J]. Life Sci, 2020, 258: 118231. doi: 10.1016/j.lfs.2020.118231.
[20] Li L, Xu DB, Zhao XL, et al. Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer[J]. Arch Gynecol Obstet, 2013, 288(1): 155-165.
[21] Laine A, Nagelli SG, Farrington C, et al. CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis[J]. Cancer Res, 2021, 81(16): 4319-4331.
[22] Cao C, Han P, Liu L, et al. Epithelial cell transforming factor ECT2 is an important regulator of DNA double-strand break repair and genome stability[J]. J Biol Chem, 2021, 297(3): 101036.
[23] Bai X, Yi M, Xia X, et al. Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA[J]. Cancer Manag Res, 2018, 10: 4039-4050. doi: 10.2147/CMAR.S170033.
[24] Sun BY, Wei QQ, Liu CX, et al. ECT2 promotes proliferation and metastasis of esophageal squamous cell carcinoma via the RhoA-ERK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(15): 7991-8000.
[25] Tong N, He Z, Ma Y, et al. Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor-glioma therapy?[J]. Front Cell Dev Biol, 2021, 9: 706286. doi: 10.3389/fcell.2021.706286.
[26] 许欣, 张颖, 陈超. 免疫细胞在子宫内膜癌中作用的研究进展[J]. 医学综述, 2021, 27(23): 4656-4660. XU Xin, ZHANG Ying, CHEN Chao. Research progress on the role of immune cells in endometrial cancer[J]. Medical Recapitulate, 2021, 27(23): 4656-4660.
[27] Crumley S, Kurnit K, Hudgens C, et al. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8⁺ lymphocytes[J]. Mod Pathol, 2019, 32(3): 396-404.
[28] Xu D, Wang Y, Wu J, et al. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway[J]. Cell Death Dis, 2021, 12(2): 162.
[29] Szczerba BM, Castro-Giner F, Vetter M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature, 2019, 566(7745): 553-557.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed